

Edgar Filing: REPLIGEN CORP - Form 8-K

REPLIGEN CORP  
Form 8-K  
April 09, 2002

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 5, 2002

REPLIGEN CORPORATION  
(Exact Name of Registrant as Specified in its Charter)

DELAWARE (State or Other Jurisdiction of Incorporation)	000-14656 Commission File Number)	04-2729386 (I.R.S. Employer Identification No.)
---	---	---

117 Fourth Avenue, Needham, Massachusetts (Address of principal executive offices)	02494 (Zip Code)
--	---------------------

Registrant's telephone number, including area code: (781) 449-9560

No change since last report  
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On April 5, 2002, Repligen Corporation announced that the United States Food and Drug Administration (FDA) has granted approval to market SecreFlo(TM) (synthetic porcine secretin), the first synthetic version of the hormone secretin. SecreFlo(TM) has been approved for stimulation of pancreatic secretions.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

- (a) Financial Statements of Business Acquired: None required.
- (b) Pro Forma Financial Information: None required.
- (c) Exhibits:

Exhibit No.	Description
-----	-----
99.1	Press release of the Company dated April 5, 2002.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPLIGEN CORPORATION

Edgar Filing: REPLIGEN CORP - Form 8-K

By: /s/ Walter C. Herlihy

-----

Name: Walter C. Herlihy

Title: President and Chief Executive Officer

Date: April 9, 2002

-2-

EXHIBIT INDEX

Exhibit No.

-----

99.1

Description

-----

Press release of the Company dated April 5, 2002.

-3-